Eli Lilly and Company (NYSE:LLY) Shares Up 1.9% – Here’s Why

Eli Lilly and Company (NYSE:LLY) rose 1.9% during mid-day trading on Wednesday . The stock traded as high as $1,093.00 and last traded at $1,085.3570. Approximately 2,535,932 shares traded hands during mid-day trading, a decline of 20% from the average daily volume of 3,179,649 shares. The stock had previously closed at $1,064.74.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly announced agreements to acquire three privately held vaccine developers — Curevo, LimmaTech Biologics, and Vaccine Company — in deals worth up to about $3.83 billion, signaling a major push into infectious disease prevention and broadening its pipeline. Lilly announces three acquisitions to build infectious disease portfolio
• Positive Sentiment: The acquisitions give Lilly exposure to vaccine targets including shingles, bacterial infections, and Epstein-Barr virus, which investors view as a sign the company is using cash flow from its obesity drugs to build new growth engines. Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
• Positive Sentiment: Analysts and market commentary have continued to highlight Lilly’s strong momentum and long-term leadership in weight-loss drugs, reinforcing confidence that the stock’s core obesity franchise remains a major earnings driver. Here’s Why Eli Lilly (LLY) is a Strong Momentum Stock
• Neutral Sentiment: Lilly also said it will participate in Goldman Sachs’ Global Healthcare Conference on June 9, an upcoming investor-relations event that may provide updates but does not change fundamentals by itself. Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
• Neutral Sentiment: Several articles noted that President Trump bought Lilly shares in Q1, but commentary emphasized that the company’s fundamentals and pipeline are the bigger driver for investors than any single insider-style purchase. President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too?

Analyst Upgrades and Downgrades

LLY has been the topic of several research analyst reports. CICC Research raised their price target on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 11th. Cantor Fitzgerald lifted their price objective on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an “overweight” rating in a report on Friday, May 1st. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a report on Tuesday, March 10th. Jefferies Financial Group lifted their price objective on Eli Lilly and Company from $1,300.00 to $1,330.00 in a report on Thursday, May 21st. Finally, Rothschild & Co Redburn lifted their price objective on Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,227.00.

Eli Lilly and Company Stock Performance

The stock has a market capitalization of $1.02 trillion, a price-to-earnings ratio of 38.56, a price-to-earnings-growth ratio of 1.16 and a beta of 0.48. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The stock’s 50-day simple moving average is $946.28 and its 200 day simple moving average is $1,006.64.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period in the previous year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts expect that Eli Lilly and Company will post 35.82 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Hedge Funds Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Maryland Capital Advisors Inc. bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $25,000. Osbon Capital Management LLC bought a new position in Eli Lilly and Company in the 4th quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC raised its position in Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after purchasing an additional 16 shares during the last quarter. Basso Capital Management L.P. acquired a new position in Eli Lilly and Company during the 4th quarter worth $30,000. Finally, 10Elms LLP lifted its holdings in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after buying an additional 10 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.